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Background: Diabetic foot ulcers (DFUs) represent a significant source of morbidity and an enormous financial
burden. Standard care for DFUs involves systemic glucose control, ensuring adequate perfusion, debridement of
nonviable tissue, off-loading, control of infection, local wound care and patient education, all administered by a
multidisciplinary team. Unfortunately, even with the best standard of care (SOC) available, only 24% or 30% of DFUs
will heal at weeks 12 or 20, respectively.
The extracellular matrix (ECM) in DFUs is abnormal and its impairment has been proposed as a key target for new
therapeutic devices. These devices intend to replace the aberrant ECM by implanting a matrix, either devoid of cells
or enhanced with fibroblasts, keratinocytes or both as well as various growth factors. These new bioengineered skin
substitutes are proposed to encourage angiogenesis and in-growth of new tissue, and to utilize living cells to
generate cytokines needed for wound repair.
To date, the efficacy of bioengineered ECM containing live cellular elements for improving healing above that of a
SOC control group has not been compared with the efficacy of an ECM devoid of cells relative to the same SOC.
Our hypothesis is that there is no difference in the improved healing effected by either of these two product types
relative to SOC.
Methods/Design: To test this hypothesis we propose a randomized, single-blind, clinical trial with three arms: SOC,
SOC plus DermagraftW (bioengineered ECM containing living fibroblasts) and SOC plus OasisW (ECM devoid of
living cells) in patients with nonhealing DFUs. The primary outcome is the percentage of subjects that achieved
complete wound closure by week 12.
Discussion: If our hypothesis is correct, then immense cost savings could be realized by using the
orders-of-magnitude less expensive acellular ECM device without compromising patient health outcomes. The
article describes the protocol proposed to test our hypothesis.
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Diabetes affects nearly one-third of the adult population
in the United States [1]. For individuals with diabetes,
the lifetime probability of developing a diabetic foot
ulcer (DFU) is estimated at 10 to 25% [2]. DFUs repre-
sent a significant source of morbidity and an enormous
financial burden [3,4]. Diabetes is the leading cause of
nontraumatic lower-extremity amputations in the United
States [1] and a DFU is often the initial insult leading to
these amputations [5]. The pathophysiology of DFUs is
thought to result from the combined comorbidities of
neuropathy, vascular deficits, impaired immunity, infec-
tion and trauma, all occurring in no particular order and
overlapping to produce a vicious cycle [6]. The standard
of care (SOC) for DFUs involves systemic glucose con-
trol, ensuring adequate extremity perfusion, debridement
of nonviable tissue, off-loading, control of infection, local
wound care and patient education, all administered by a
multidisciplinary team [7-10]. Unfortunately, even with
the best SOC available, only 24% or 30% of DFUs will
heal at weeks 12 or 20, respectively [11].
Classic wound repair has been described as a rela-
tively linear process (albeit with significant complexity
and overlap), progressing through three general phases:
inflammatory, including platelet aggregation, release of
proinflammatory cytokines and recruitment of neutro-
phils and macrophages; proliferative, including fibro-
blast proliferation, angiogenesis and formation of
granulation tissue and keratinocyte proliferation and
re-epithelialization; and remodeling, the longest phase,
including myofibroblast transformation and slow re-
structuring of the healed wound to increase its
strength [6,12].
In nonhealing DFUs the normal healing process is
stalled. The exact mechanisms involved in this impair-
ment are not fully understood but an increasing number
of pathways are suggested with varying levels of evidence
and are summarized herein as reviewed in a number of
recent excellent articles [13-18]. Hyperglycemia is
thought to adversely affect healing by increased levels of
advanced glycation end products that inhibit normal
extracellular matrix (ECM) deposition and upregulate
activity of matrix metalloproteinases (MMPs). Prolonged
hyperglycemia may also offset the delicate balance be-
tween reactive oxygen species and various antioxidants
by depletion of nicotinamide adenine dinucleotide
phosphate on one hand and increasing reactive oxygen
species production on the other. DFUs have increased
activity of MMPs coupled with decreased activity
of MMP inhibitors (tissue inhibitors of metalloprotei-
nases). Fibroblasts in DFUs are often senescent, ex-
hibit decreased proliferation and are less responsive
to growth factors when compared with fibroblasts
from age-matched diabetic controls without ulceration.Keratinocytes in diabetic wounds exhibit impaired mi-
gration, which may be mediated by c-Myc and β-catenin.
A drastic decrease in available inorganic phosphate leads
to decreased levels of ATP in DFUs – a devastating blow
to all healing-related processes. Immune response is
impaired, with reduced inflammatory cell recruitment at
the initial phase and later a skewed immune response
towards macrophage and B-cell infiltrates. That phase is
also characterized by increased TNFα and IL-1β expres-
sion, which are known MMP stimulators. Leukocyte
function and intracellular killing are impaired in DFUs,
rendering these ulcers exceptionally susceptible to super-
ficial infections and resistant biofilms. Neuropathy
leads to decreased levels of neuropeptides that nor-
mally contribute to healing. In addition, neuropathy
reduces capillary blood flow. Impaired gap junction
function has recently immerged as an additional
pathological mechanism leading to impaired wound
healing in DFUs.
As described above, the ECM is abnormal in DFUs
and its impairment has been proposed as a key target
for new therapeutic devices [19]. These devices intend to
replace the aberrant ECM by implanting a matrix, either
devoid of cells or enhanced with fibroblasts, keratino-
cytes or both as well as various growth factors. These
new bioengineered skin substitutes are proposed to en-
courage angiogenesis and in-growth of new tissue, and
to utilize living cells to generate cytokines needed for
wound repair. DermagraftW (Shire Regenerative Medi-
cine, Inc. La Jolla, California, United States ) is one ex-
ample of bioengineered matrix supplemented with
fibroblasts (cellular matrix (CM)). Other “new-gener-
ation” ECM replacement tissues, devoid of cellular com-
ponents, have been created for wound repair, and the
OasisW (Healthpoint, Ltd Fort Worth, Texas, United
States ) acellular matrix (ACM) is an example of this cat-
egory. Interestingly, in industry-supported randomized
controlled trials, the reported rates of wound closure at
week 12 are approximately 50% for both devices [20,21].
A success rate of 50% represents about 20% added bene-
fit to the use of such devices over the SOC. This min-
imal benefit may be disproportionate to the expenditure
these devices accumulate (for example, up to $1,800 per
application, and up to eight applications as the recom-
mended regimen).
The efficacy of bioengineered ECM containing live cel-
lular elements (CM) for improving healing above that of
a SOC control group has not to date been compared
with the efficacy of an ECM devoid of cells (ACM) rela-
tive to the same SOC. Our hypothesis is that there is no
difference in the improved healing effected by either of
these two product types relative to the SOC. If this hy-
pothesis is correct, then immense cost savings could
be realized by using the orders-of-magnitude less
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patient health outcomes. To test this hypothesis we pro-
posed a randomized, single-blind, clinical trial with three
arms: SOC, SOC plus DermagraftW (bioengineered ECM
containing living fibroblasts) and SOC plus OasisW (ECM
devoid of living cells) in patients with nonhealing DFUs.
Methods/Design
Participants
The study protocol is approved by both the Veterans
Affairs’ Institutional Research and Development Com-
mittee and their Institutional Review Board (IRB). Study
participants are veterans eligible for Veterans Affairs’
medical benefits. Patients are recruited from all clinics at
the Veterans Affairs’ Northern California Healthcare
System via provider referral and IRB-approved flyers.
The study is supported by a Veterans Affairs’ MERIT
award (project ID SURG-369-10S). During the “run-in”
phase (see Table 1) all participants are screened for eligi-
bility based on the inclusion and exclusion criteria. All
study-related procedures (except diagnostic tests such as
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DermagraftW (Advanced BioHealing, Inc. La Jolla, California, United States), OasisW (H
version 2; SOC, standard of care; Tx, treatment.staff at participating Veterans Affairs Northern Califor-
nia Healthcare System wound centers.
Inclusion criteria
 Institutional Review Board (IRB) Informed Consent
Form is signed and dated prior to any study-related
activities.
 Area of the study ulcer after debridement is between
1 and 25 cm2 at week 0/visit 3.
 Subject is between 18 and 85 years of age.
 Subject's highest Ankle Brachial Pressure Index
(ABPI)/Ankle Arm Index (AAI) ≥ 0.80 and < 1.4
(Highest ABPI/AAI value from three
measurements within last 6 months shall apply) or
toe–arm index ≥ 0.6.
 Patient has one or more diabetic ulcers on the target
foot with only one ulcer selected as the study
(target) ulcer. The target ulcer must be at least 4 cm
from a nontarget ulcer and, in the investigator’s
opinion, be unlikely to coalesce with another ulcer
within 12 weeks of randomization.to 10 (weeks
, treatment
riable)
Visits 11 to 14





Visits 16 to 19
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follow-up
X
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ealthpoint, Ltd, Fort Worth, Texas, United States). SF-36v2™, Short Form-36,
Lev-Tov et al. Trials 2013, 14:8 Page 4 of 8
http://www.trialsjournal.com/content/14/1/8 Subject's study ulcer is full thickness and does not
extend to bone, muscle, or tendon.
 Subject's study ulcer has been present at least 4
weeks prior to the initial screening (visit 1) or 6
weeks at randomization (visit 3).
 Subject has been diagnosed with type 1 or type 2
diabetes and hemoglobin A1c < 10%.
 Study ulcer has no clinical feature of infection (two
signs of inflammation and elevated bacterial load of
the wound).
 Female subjects of childbearing age potential have a
negative pregnancy test and are lactating for the
duration of the study.
 Subject understands the requirements of this study and
is willing to comply with all the study requirements.
Exclusion criteria
 Subject is diagnosed with cancer and is undergoing
treatment with immunosuppressive or
chemotherapeutic agents, radiotherapy or systemic
corticosteroids < 30 days before enrollment.
 Subject is diagnosed with HIV/AIDS.
 Subject is diagnosed with any bleeding disorders.
 Subject is diagnosed with any connective tissue
diseases.
 For female subjects, the subject is pregnant or lactating.
 Subject has a history of illicit drug use within 1 year
of enrollment.
 In the past year, the subject experienced episodes of
drinking more than five alcoholic beverages in <2
hours and/or drinking alcohol became a problem in
their interpersonal relationships, work, driving and/
or their behavior in general.
 Subject has any active infected wounds or
osteomyelitis (confirmed by bone biopsy, magnetic
resonance imaging or bone scan).
 Subject had Doppler examination within the last 365
days, and it demonstrated reflux > 0.5 seconds.
 Subject is diagnosed with active Charcot as
described by Saunder’s classification system.
 Subject manifests signs of poor nutritional status
and/or albumin level < 2.9 g/dl.
 Subject received DermagraftW and/or OasisW in the
last 60 days.
 Study ulcer size < 1.0 cm2 or >25 cm2.
 Subject has any porcine allergy or cow product allergy.
 Subject’s recent (last 30 days) chemistry test’s serum
creatinine is two times above the upper limit of
normal and/or liver enzymes (AST, ALT) are three
times above the upper limit of normal.
 Between week −2/visit 1 and week 0/visit 3
(randomization) the study ulcer decreased in size by
> 40%, or increased in size by > 50%.DermagraftW (Advanced BioHealing, Inc. La Jolla,
California, United States), OasisW (Healthpoint, Ltd Fort
Worth, Texas, United States).
Participant consent
Detailed informed consent is obtained from all partici-
pants and a HIPAA Health Insurance Portability and Ac-
countability Act release form is signed. Prior to any
study-related intervention, study staff provide each pro-
spective subject with a detailed explanation of the nature
and purpose of the trial. Once study staff are assured
that the prospective subject understands all study proce-
dures and potential implications, an IRB-approved
informed consent form is signed. The signed copy
becomes part of the subject’s record. An additional copy
of the informed consent is provided to the subject for
future reference.
Criteria for withdrawal
Subjects are informed that they may withdraw from the
trial for any reason at any time and that the investigator
may decide to withdraw them from the trial for safety-
related issues. Study staff explain that failure to comply
with the study’s procedure may result in withdrawal
from the trial. In the case of such an event, the reason
for withdrawal is documented in the subject’s file and
the subject is referred to the wound clinic for further
follow-up.
Participant compliance
Overall participant compliance with study-related proce-
dures is assessed at each study visit by the staff. Specific-
ally, detailed questioning regarding compliance with off-
loading and any tampering with study-related dressings
is performed at each study visit and any deviations are
noted in the subject’s file for later analysis.
Summarized details of products compared (interventions)
The CM of this study, DermagraftW, is a cryopreserved
human fibroblast-derived dermal substitute composed of
viable newborn foreskin fibroblasts, seeded onto a bioab-
sorbable polyglactin mesh. The product is supplied fro-
zen (−75°C) in a clear bag containing a 2 inch×3 inch
matrix [22]. The product is stored according to the man-
ufacturer’s instructions and records of quality control,
including constant temperature monitoring, are kept by
study staff. DermagraftW is applied according to the
manufacturer’s instructions [22].
The ACM of this study, OASISW, is a bioabsorbable
ECM derived from porcine small intestinal submucosa.
The product is processed using proprietary methods to
retain its original structure while stored at room
temperature [23]. The product is stored and applied
according to the manufacturer’s instructions [23].
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& Nephew Largo, Florida, United States), AdapticW
(Johnson & Johnson Gargrave, Skipton, United Kingdom )
and gauze. This dressing also serves as the secondary
dressing for the two intervention arms. If a subject has an
allergy to iodine products, then Bacitracin antibiotic oint-
ment is used as a replacement for Iodosorb.
We will provide all subjects with a removable walking
boot, such as a camwalker or diabetic conformer Bledsoe
boot. The clinician will make further accommodation/
adjustment to offload plantar ulcers with excavation or
aperature using plastazote, foam or felt padding. Those
patients that use exclusively manual or motorized wheel-
chairs will be identified to differentiate patients that are
fully ambulatory from those with limited ambulatory
capacity. While total contact casting is considered the
gold standard for offloading plantar ulcers by many aca-
demicians, in our experience total contact casting is not
in standard use owing to time constraints with cast ap-
plication and accessibility to materials. Indeed, a recent
study found that fewer than 2% of diabetic foot specia-
lists utilize this form of offloading [24]. Our study there-
fore models the standard care for all arms after realistic
clinical practice.
All products used in this trial are approved by the
Food and Drug Administration for use in treatment of
DFUs.
Hypothesis (objectives)
There is no significant difference in healing at weeks 12
and week 20 or in the rate of healing when treating
DFUs with SOC as compared with CM or ACM.
Alternative hypothesis
There is a significant difference in healing at weeks 12
and week 20 or in the rate of healing when treating
DFUs with SOC as compared with CM or ACM.
Primary outcome
The primary outcome is the percentage of subjects that
achieved complete wound closure by week 12. Complete
healing is defined as full re-epithelialization of the ulcer
with no drainage, or callus formation with underlying
ulcer on two consecutive visits 1 week apart. Callus
(hyperkeratosis) formation will be debrided at the wound
site to determine whether complete closure has been
obtained. The wound is deemed healed if there is no
underlying open lesion after debridement (complete
epithelialization).
Secondary outcomes
The first secondary outcome is the percentage of subjects
that achieved complete wound closure by week 20.
Complete healing will be defined as full re-epithelializationwith no drainage, or callus formation with underlying ulcer
on two consecutive visits 1 week apart.
Another secondary outcome is the rate of wound heal-
ing to achieve complete closure based on weekly wound
area measurements.
Third is the incidence of ulcer recurrence at week 20.
Recurrence will be defined as an ulcer occurring at the
same location as the healed study ulcer.
Fourth is the association of wound healing (overall and
given a particular treatment) with the following wound
characteristics: peri-ulcer erythema, induration, tender-
ness, pain, local warmth, size, depth, undermining, ulcer
location, ulcer age at presentation, ulcer precipitating
event and total wound assessment score at presentation.
Another outcome is the association of wound healing
(overall and given a particular treatment) with the fol-
lowing patient characteristics on presentation: age, sex,
body mass index, smoking history, family history of dia-
betes, complete blood count results, chemistry panel
results, erythrocyte sedimentation rate and C-reactive
protein serum concentration and hemoglobin A1C
serum concentration.
Sixth is the association of a particular treatment with
the incidence of the following during the study period:
cellulitis, osteomyelitis, acute Charcot disease and over-
all adverse events rate.
Another outcome is the association of a particular
treatment with a change in quality of life assessments
(quality-adjusted life-years).
The final secondary outcome is cost-effectiveness of a
particular treatment compared with SOC.
Sample size
Based on previous trials [20,21] it is estimated that ap-
proximately 50% of the subjects in the intervention arms
will achieve complete wound closure at week 12 (pri-
mary outcome) and approximately 25% of the SOC arm
will achieve complete wound closure by week 12. The
sample size was estimated based on 80% power and a
0.05 significance level to detect a 25% difference between
the intervention and control arms (Stplan 4.5 statistical
software, Department of Biomathematics, University of
Texas MD Anderson Cancer Center, Houston, TX, USA,
2010). Based on the method of normal approximation to
the arcsin transformation of the binomial distribution
and, to be conservative, a two-sided test, enrollment of
57 subjects in each arm is required.
Randomization
Sequence generation
Since healing has been shown to depend on age and race
[25,26], randomization was done in small blocks (six
subjects per block) in order to match subjects according
to age groups (< 50 years old, 50 through 59 years old,
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and race (black and nonblack). We used a computer-
generated algorithm to randomly assign treatments to
subjects within a block and to randomly determine the
block sequence. Subjects presenting to the study will be
entered into their appropriate block in a strict chrono-
logical order.
Allocation concealment and implementation
The randomization table was generated prior to study
initiation by the study’s biostatistician. Allocation is con-
cealed by the Northern California Veterans Affairs Inves-
tigational Drug Service, an independent third party, until
the moment of randomization.
Blinding
Owing to the nature of the interventions studied,
complete blinding is not realistic (for example, Derma-
graftW requires storage at −75 ± 10°C and a specific ma-
nipulation immediately prior to application). An
independent observer was therefore assigned to assess
the primary and secondary outcomes. Clinical images
will be captured at each visit before and after debride-
ment and will be de-identified and uploaded to an exter-
nal server (Silhouette CentralW Aranz Medical,
Christchurch, New Zealand). The observer will log on to
the server independently and determine whether the
wound has closed or not. In addition, the observer will
determine whether the margins used for area measure-
ment are accurate.
Statistical methods
All data will be analyzed based on intention to treat.
The primary outcome, wound closure by week 12, will
be analyzed using the chi-square test or Fisher’s exact
test when appropriate to compare the percentages of
subjects with complete closure in each group. We will
also perform exploratory analysis with logistic regres-
sion, using complete wound closure at 12 weeks as the
dependent variable and the independent variables would
include the characteristics described as the fourth to
sixth items in Secondary outcomes above. We will run
preliminary analysis on selected covariates to determine
whether there are significant differences.
Cost-effectiveness analysis will be performed to com-
pare the treatment groups DermagraftW and OasisW and
the standard care group using the analysis of variance F
test or Kruskal–Wallis test according to the data distri-
bution pattern. If significant, we will further analyze with
pair-wise comparisons using Tukey’s test or Dunn’s test.
A multiple-comparison post-hoc test for Kruskal–Wallis
analysis will be performed with the Statistical Analysis
System (Cary, NC, USA) macro developed by Elliott and
Hynan [27].We will evaluate the cost-effectiveness of OasisW com-
pared with DermagraftW and the SOC by measuring
quality-adjusted life-years as the measure of effective-
ness, based on results obtained from Short Form-36 (SF-
36v2™) questionnaires. Multiple regression will be used
to evaluate continuous dependent variable outcomes, in-
cluding change in SF-36v2™ physical and mental compo-
nent summaries scores between baseline and the end of
the study.
Rates of healing among the groups will be analyzed
using a log-rank test to compare the time of healing
within 20 weeks.
Secondary outcomes such as complete healing at 20
weeks and rate of ulcer recurrence at 20 weeks will be
analyzed using chi-square tests or Fisher’s exact tests
when appropriate. In addition, demographics, smoking
history, and other characteristics mentioned in Second-
ary outcomes will be summarized in a table. For com-
parison of nominal categorical secondary outcome
variables, we will use the chi-square test or Fisher’s exact
test when appropriate. For comparison of ordinal cat-
egorical variables, we will use the Wilcoxon rank-sum
test (for two independent group comparisons) and the
Kruskal–Wallis test (for three independent group
comparisons).
Data management
Data will be managed by the study’s biostatistician (C-SL)
at the University of California Davis Clinical and Transla-
tional Science Center. Data will be automatically imported
from digital subject records into pre-designed spread
sheets using ExcelW and analyzed using Statistical Analysis
System, version 9.3 [28].
Plan and trial design
This is a randomized, controlled, single-blind, trial com-
paring the efficacy of ACM with that of CM in treatment
of DFUs. A total of 171 subjects will be enrolled and
randomly assigned to one of three treatment groups:
ACM, CM and SOC. Subjects are followed for a total of
30 weeks in three major phases: run-in phase, treatment
phase and follow-up phase. The study’s procedures are
detailed below.
Run-in phase
During this 2-week period (weeks −2 through 0) pro-
spective subjects are seen on a weekly basis and rigor-
ously evaluated for eligibility. Once informed consent is
secured, detailed health-related history is solicited and a
thorough physical examination is performed. Compre-
hensive lower-extremity ulceration evaluation is done
(including imaging and area measurements) and compli-
ance with an off-loading device is assessed. The follow-
ing laboratory studies are ordered to exclude
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mass index, pregnancy test, Ankle-Brachial Index, quan-
titative bacterial cultures, fungal cultures, tissue path-
ology, complete blood count, comprehensive metabolic
panels (including liver enzymes and albumin levels),
erythrocyte sedimentation rate, C-reactive protein level,
hemoglobin A1C level and lower-extremity X-rays. Once
eligibility is established, subjects are randomized (as
described above) to one of three treatment arms. SF-36
questionnaires are filled out by the subjects.
Treatment phase
This phase is divided into a variable treatment period
(weeks 0 through 7) and a SOC treatment period (weeks
8 through 11). Subjects will be evaluated on a weekly
basis.
During the variable treatment period, subjects in each
arm will receive its corresponding primary dressing
treatment (that is, ACM, CM or SOC). During each visit,
vital signs will be measured, a comprehensive lower-
extremity assessment will be performed (including pho-
tography and ulcer area measurement), health status and
medication changes will be recorded and adverse events
will be assessed. Compliance with the off-loading device
will also be assessed.
During the SOC treatment phase the primary dressing
applied to all subjects will be identical and will comprise
the SOC dressing. The rest of the visit will be identical
to the variable treatment period as described above.
On week 12, a study endpoint visit will be conducted.
During this visit, vital signs will be measured, a compre-
hensive lower-extremity assessment will be performed
(including photography and ulcer area measurement),
health status and medication changes will be recorded
and adverse events will be assessed. Compliance with
the off-loading device will also be assessed. In addition,
the SF-36 questionnaire is filled out for the second time
by the subjects and repeat complete blood count and
comprehensive metabolic panels are ordered. SOC treat-
ment will be provided to all subjects.
Follow-up phase
This phase is comprised of four monthly visits (weeks 13
through 28). During each visit, vital signs are measured,
a comprehensive lower-extremity assessment is per-
formed (including photography and ulcer area measure-
ment), health status and medication changes are
recorded and adverse events are assessed. Compliance
with the off-loading device is also assessed. During the
follow-up phase the primary dressing applied to all sub-
jects is identical and will comprise the SOC dressing.
SOC treatment is provided to all subjects.
In the event of early wound closure (before week 12),
the subject will return for follow-up visits every 4 weeksfrom the confirmatory visit and in week 12 or in week
12 only, whichever comes first, and will return to the
schedule above thereafter. In the event of failure to heal
after week 12, subjects will be followed at the wound
clinic based on clinical need but will return for all
follow-up phase mandated visits.Ethical considerations
The DOLCE trial is approved by the Veterans Affairs
Northern California Healthcare System IRB and the Re-
search and Development Committee. The primary inves-
tigators will ensure that the study is conducted in full
compliance with the protocol and IRB regulations as
well as international standards on human subjects’ re-
search. The primary investigators will ensure compliance
with institutional regulations as well as local and na-
tional law. Compliance will be administered by a dedi-
cated, certified Clinical Research Coordinator. A data
monitoring committee has been set up to review safety
data. All adverse events will be reported to the IRB as
stipulated by the IRB in its protocol-approval letter.Discussion
The DOLCE trial is a randomized, single-blind, com-
parative efficacy trial to assess the difference between
ACM, CM and SOC in the treatment of DFUs. As the
healthcare-related industry and science are marching to-
wards development of increasingly complex and expen-
sive devices, it is crucial to regularly and rigorously
reassess the efficacy of various available interventions.
Healthcare providers are constantly presented with new
devices and need solid evidence to support clinical deci-
sion-making. However, many studies designed to provide
such evidence are industry supported, and thus subject
to concerns regarding inherent bias – if not with the de-
sign and execution of the trial, then certainly with the
dissemination of the results, should those results not
favor the product whose manufacturer sponsored the
trial ([29]). In addition, in this study, subanalysis may
allow for a better understanding of the indications for
preferring one device over the other. Practicing within
financial constraints is especially important when treat-
ing a prevalent condition such as DFUs. Providing the
wound care specialist with the data to support the use of
less expensive treatments without compromising patient
outcomes could potentially save the healthcare system
significant resources. The DOLCE trial is an attempt to
provide wound care specialists with relevant evidence to
an overwhelming clinical problem in order to support
meaningful clinical decision-making. In addition, we
hope to set an example for the importance of independ-
ent, investigator-initiated comparative efficacy research.




ACM: acellular matrix; CM: cellular matrix; DFU: diabetic foot ulcer;
ECM: extracellular matrix; IL: interleukin; IRB: Institutional Review Board;
MMP: matrix metalloproteinase; SF-36: Short Form-36; SOC: standard of care;
TNF: tumor necrosis factor.
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